Atossa Therapeutics ends 2024 with $71.1M cash; advances (Z)-endoxifen for metastatic breast cancer

ATOSSA THERAPEUTICS, INC.

Cash and equivalents $71.1M, no debt; operating expenses fell to $27.6M from $31.4M in 2023.
Strategic pivot to pursue metastatic breast cancer indication for (Z)-endoxifen, citing streamlined regulatory path.
Phase 2 EVANGELINE trial of (Z)-endoxifen showed Ki-67 ≤10% response rate >85% across doses; amended protocol to compare 40mg + OFS vs exemestane + OFS.
Phase 2 KARISMA-Endoxifen: 1mg and 2mg doses reduced mammographic breast density by 17.3 and 23.5 percentage points (p<0.01) vs placebo 0.27 pts.
R&D expenses down 19% to $14.1M; G&A expenses down 4% to $13.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.